TABLE I.
Omalizumab Dosing Table in ICATA
| Baseline IgE (IU/mL) | Weight (kg) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20–25 | >25–30 | >30–40 | >40–50 | >50–60 | >60–70 | >70–80 | >80–90 | >90–125 | >125–150 | >150 | |
| 0–30 | Do Not Dose | ||||||||||
| ≥ 30–100 | 75*† | 75*† | 75*‡ | 150* | 150* | 150* | 150* | 150* | 300* | 300* | |
| >100–200 | 150*† | 150*† | 150*‡ | 300* | 300* | 300* | 300* | 300* | 225§ | 300§ | |
| >200–300 | 150*† | 150*† | 225*‡ | 300* | 300* | 225§ | 225§ | 225§ | 300§ | 375§ | |
| >300–400 | 225*† | 225*† | 300*‡ | 225§ | 225§ | 225§ | 300§ | 300§ | |||
| >400–500 | 225*† | 300*† | 225§‡ | 225§‡ | 300§ | 300§ | 375§ | 375§ | |||
| >500–600 | 300*† | 300*† | 225§‡ | 300§ | 300§ | 375§ | |||||
| >600–700 | 300*† | 225§† | 225§‡ | 300§‡ | 375 | ||||||
| >700–800 | 225§† | 225§† | 300§† | 375§† | Do Not Dose | ||||||
| >800–900 | 225§† | 225§† | 300§† | 375§† | |||||||
| >900–1000 | 225§† | 300§† | 375§† | ||||||||
| >1000–1100 | 225§† | 300§† | 375§† | ||||||||
| >1100–1200 | 300§† | 300§† | |||||||||
| >1200–1300 | 300§† | 375§† | |||||||||
| >1300 | Do Not Dose | ||||||||||
Values are milligrams per dose; empty cells are not eligible for dosing. This expanded omalizumab dosing table was consistent with the omalizumab FDA-approved safety and tolerability studies in ages 6 to 12 years, and approved for use in ICATA.
From N Engl J Med. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. Volume 364, pp. 1005–15. Copyright © 2011 Massachusetts Medical Society. Reprinted with permission.12
*
Dosing once every 4 weeks.
†
Added from FDA dosing table.
‡
Dose changed from FDA dosing table.
§
Dosing once every 2 weeks.